Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
Détails
ID Serval
serval:BIB_605A7A84D42A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
Périodique
European Journal of Cancer
ISSN
0959-8049 (Print)
Statut éditorial
Publié
Date de publication
03/1999
Volume
35
Numéro
3
Pages
410-2
Notes
Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Mar
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Mar
Résumé
Temozolomide, an oral imidazotetrazine derivative, was given to 31 patients with advanced soft tissue sarcoma. The dose of 750 mg/m2 was divided over 5 consecutive days, and escalated to 1000 mg/m2 over 5 days at cycle 2 if myelosuppression no worse than common toxicity criteria grade 2 was noted in the first 28-day cycle. A total of 99 treatment cycles were given to 31 patients. The drug was well tolerated, with nausea and vomiting as the most common side-effects. Only one partial tumour response was documented, giving a response rate of 3.33%, 95% confidence interval, (CI) 0.1-17.2%. The median time to progression was 8 weeks and the median survival was 27 weeks. These results indicate that temozolomide in this schedule is not active as second-line treatment in advanced soft tissue sarcoma.
Mots-clé
Adult
Aged
Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use
Dacarbazine/adverse effects/*analogs & derivatives/therapeutic use
Female
Humans
Male
Middle Aged
Sarcoma/*drug therapy
Survival Analysis
Treatment Outcome
Pubmed
Web of science
Création de la notice
28/01/2008 9:32
Dernière modification de la notice
20/08/2019 15:17